Akademik Veri Yönetim Sistemi
EUROPEAN JOURNAL OF GERIATRICS AND GERONTOLOGY, cilt.7, sa.3, ss.178-185, 2025 (ESCI, Scopus, TRDizin)
Objective: This study aims to determine the prevalence and risk factors of sarcopenia in people living with human immunodeficiency virus (PLWH) aged 50 years and over. Materials and Methods: Ninety individuals who live with human immunodeficiency virus (HIV) aged 50 years and over, who were under followup in our outpatient clinic between May 2021 and October 2021, were included in the study. Demographic, clinical, laboratory data, and drug information of the patients, were reviewed from medical records. Sarcopenia tests were conducted, and fracture risk assessment tool scores of the patients were calculated. Results: In our study, the prevalence of sarcopenia in PLWH aged 50 years and over was found to be 40% (8.9% definite sarcopenia, 31.1% probable sarcopenia). No association was found between elapsed time since diagnosis of HIV infection, initial CD4 T lymphocyte count, rate of antiretroviral therapy (ART) usage, duration of ART usage, ART regimens with sarcopenia. In our study, 10-year probability of major osteoporotic fracture risk and hip fracture risk was significantly higher in the male group with sarcopenia compared to the non-sarcopenic group. Conclusion: The prevalence of sarcopenia in PLWH aged 50 years and over, was found to be higher compared to the general population. It was observed that individuals with sarcopenia had a higher risk of fractures. Since sarcopenia is associated with falls, fractures, disability, hospitalization, and mortality, screening for sarcopenia in PLWH aged 50 years and over may be beneficial in preventing adverse outcomes.